Ascensia Diabetes Care Archives - Medical Design Sourcing

Ascensia, Senseonics announce new CGM cost savings

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care and Senseonics today announced an extension to their Eversense Payment Assistance and Simple Savings (PASS) program.

The program aims to help people in the U.S. access the Eversense E3 continuous glucose monitor (CGM) more affordably. It offers major savings for eligible individuals looking to experience the benefits of the long-term, implantable CGM.

Eversense E3, a 180-day CGM, requires two sensor insertion and removal procedures per year. It offers a mean absolute relative difference (MARD — an accuracy metric for CGMs) of 8.5%. The system features predictive on-body alerts to never miss a critical event. Senseonics develops the sensor and Ascensia serves as the global exclusive distributor for Eversense E3.

Senseonics also has the regulatory wheels in motion for Eversense E3 with a 365-day wear time. The company expects an “imminent” submission to the FDA.

Former Tandem CCO joins Ascensia as president of CGM

Ascensia Diabetes Care parent company PHC Holdings and Senseonics announced today that Ascensia named Brian Hansen its president of CGM.

Hansen’s appointment to the newly created role at the global distributor of Senseonics’ Eversense CGM went into effect today, Feb. 6.

Responsibilities for Hansen include the global commercialization and growth of the Eversense system. The fully implantable CGM allows for the continuous measurement of glucose levels for up to six months. With longevity, it also offers features like a removable transmitter, discreet on-body vibe alerts, accuracy and a smartphone app.

Hansen previously served as chief commercial officer at insulin pump maker Tandem Diabetes Care.

Get the full story at our sister site, Drug Delivery Business News.

Here’s what diabetes tech companies are doing on World Diabetes Day

Every November, the diabetes community comes together to recognize both National Diabetes Month in the U.S. and World Diabetes Day.

World Diabetes Day falls on today, Nov. 14, to mark the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922.

In an effort to drive awareness and understanding of the chronic condition, a number of medtech companies in the diabetes space undertake efforts each year to celebrate and draw attention to the day and month recognizing the community. We compiled lists in 2021 and 2022 to share some of the initiatives brought forward by these companies.

On World Diabetes Day in 2023, here is what medtech’s diabetes community is doing:

Abbott

Abbott (NYSE:ABT) launched its new “Countdown at a Crossroads” initiative to mark National Diabetes Awareness Month.

The initiative features an animated installation promoting diabetes awareness at the Oculus Center…

Ascensia Diabetes Care inks deal to integrate blood glucose monitors in point-of-care testing

The Contour Next One blood glucose meter. [Image from Ascensia Diabetes Care]Avricore Health and Ascensia Diabetes Care announced a partnership to integrate blood glucose monitoring into point-of-care testing.

The deal aims to integrate the Contour Next-Gen and Contour Next One BGM systems into Avricore’s HealthTab PCOT platform. Both companies have the objective of supporting patients and pharmacists in Canada to better manage diabetes. The companies believe they can link daily blood glucose testing results and pattern history to a patient’s HealthTab account.

Additionally, the partnership seeks to support the utilization of each technology by enabling pharmacists and patients to take advantage of data insights.

Get the full story at our sister site, Drug Delivery Business News.

Ascensia expands payment program for Senseonics Eversense E3 CGM

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care announced today that it expanded the Eversense PASS program for the Senseonics (NYSE:SENS) Eversense E3 CGM.

Eversense PASS, a payment assistance and simple savings program, aims to enhance affordability and access to Eversense E3. Ascensia serves as the global commercial partner for Senseonics. The Senseonics continuous glucose monitor (CGM), a 180-day implantable CGM, received FDA approval in February of last year.

It features a third-generation sensor with SBA technology that enhances sensor longevity. This makes it — according to Senseonics — the longest-lasting CGM system. The fully implantable sensor requires just two insertion and removal procedures per year.

Get the full story at our sister site, Drug Delivery Business News.

Ascensia partners with Snaq on diabetes management

The Contour Next One blood glucose meter. [Image from Ascensia Diabetes Care]Ascensia Diabetes Care announced today that it entered into a global collaboration with diabetes management company Snaq.

Snaq develops an app-based solution offering insights on food and nutrition for people with diabetes. Ascensia develops the Controu blood glucose monitoring system and distributes Senseonics’ Eversense CGM systems. The companies plan to integrate technologies to help with mealtime decisions and improve diabetes management.

Get the full story at our sister site, Drug Delivery Business News.

Ascensia Diabetes integrates its Eversense CGM with Apple Health

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care announced today that it has updated its Eversense Continuous Glucose Monitoring system app to integrate with Apple Health.

The Parsippany, N.J.-based company makes the Contour Blood Glucose Monitoring (BGM) system and distributes Senseonics’ Eversense CGM system. The new Apple Health integration will allow people with diabetes using Senseonics’ Eversense CGM systems to view glucose data within the Apple Health app. In addition, they can also see other health metrics on the iPhone’s health and wellbeing platform.

Eversense CGM is a fully-implantable CGM with a sensor that has a 6-month sensor wear duration. The system transmits data to the Eversense CGM app. There, users can view, analyze and share glucose data. In addition, it alerts users to changes and trends in glucose levels as well.

The new integration allows users in all markets where Eversense is availab…

Ascensia, Senseonics partner with Nurse Practitioner Group on CGM insertion options

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) and Ascensia Diabetes Care launched a collaboration with the Nurse Practitioner Group (NPG) today.

NPG offers multidisciplinary health services and medical staffing solutions. The collaboration aims to broaden access to the Eversense E3 continuous glucose monitor (CGM) system. Senseonics developed Eversense E3 and Ascensia distributes the system as the company’s partner.

The collaboration offers convenient at-home and in-office insertion options for diabetes patients. NPG recently completed the first patient insertion of the six-month Eversense E3 sensor in Florida. It plans to expand the initiative to other key markets across the U.S. in the coming months.

Get the full story at our sister site, Drug Delivery Business News.

Ascensia launches online diabetes management, analytics platform in U.S.

[Image from Ascensia Diabetes Care]Ascensia Diabetes Care announced today that it launched its online diabetes management and analytics platform in the U.S.

Parsippany, New Jersey-based Ascensia now offers GlucoContro.online in more than 15 countries around the world. It plans for further expansion, too.

Get the full story at our sister site, Drug Delivery Business News.

Ascensia completes Senseonics Eversense E3 European launch

The Eversense E3 system. [Image from Ascensia/Senseonics]Ascensia Diabetes Care announced that it successfully completed its initial European launch for the Senseonics (NYSE:SENS) Eversense E3.

Eversense E3 represents Senseonics’ next-generation continuous glucose monitor (CGM) system. Eversense E3 can be used for up to six months (180 days). This doubles the wear time of its previous-generation CGM.

Ascensia said in a news release that its launch extends to Germany, Switzerland, Poland, Italy, Spain, Norway, Sweden, the Netherlands, and Andorra. The company began its phased rollout for Eversense E3 in August.

The system received CE mark approval in June.

Get the full story at our sister site, Drug Delivery Business News.

Senseonics wins CE mark approval for 180-day Eversense E3 CGM

The Eversense E3 system. [Image from Ascensia/Senseonics]Senseonics (NYSE:SENS) announced today that it received CE mark for the next-generation Eversense E3 CGM system.

Germantown, Maryland-based Senseonics offered its previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days).

Get the full story at our sister site, Drug Delivery Business News.

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.

From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.

Here are five of the biggest stories to come out of ATTD 2022:

Dexcom’s G7 is accurate in pediatric T1D patients

Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.

The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

Get the full story at our sister site, Drug Delivery Business News.